Kyorin Pharmaceutical Co Ltd TSE:4569:
KYORIN PHARMACEUTICAL CO LTD: KYORIN AND HINGE BIO ENTER INTO A COLLABORATION AND LICENSE AGREEMENT OF HB2198 IN JAPAN FOR SLE AND OTHER DISEASES
KYORIN PHARMACEUTICAL CO LTD: IMPACT ON CONSOLIDATED EARNINGS FORECAST FOR FISCAL YEAR ENDING MARCH 2026 IS EXPECTED TO INCLUDE UPFRONT PAYMENT TO HINGE BIO UNDER THIS AGREEMENT, WHICH WILL BE RECORDED AS SG&A EXPENSES (RESEARCH AND DEVELOPMENT EXPENSES) FOR CURRENT FISCAL YEAR